98%
921
2 minutes
20
Objective: To investigate the prognostic value of F-deoxyglucose (FDG) PET/CT metabolic parameters combined with clinicopathological features for newly diagnosed diffuse large B-cell lymphoma (DLBCL) before treatment, and analyze the relationship between tumor metabolic volume (MTV), total lesion glycolysis (TLG) and clinicopathological features.
Methods: The clinical data of 120 patients with pathologically confirmed DLBCL were retrospectively analyzed and F-FDG PET/CT was performed 1 week before treatment. The metabolic parameters including SUVmax, SUVmean, tumor-to-blood standardized uptake value ratio (TBR), tumor-to-liver standardized uptake value ratio (TLR) were obtained. MTV and TLG of the lesions were obtained with 41% of SUVmax as the threshold, and the correlation of MTV and TLG with clinicopathological features were analyzed. Progression-free survival (PFS) was calculated by follow-up for 6-153 months. Receiver operating characteristic (ROC) curve, chi-square test, Kaplan-Meier test, log-rank test and Cox proportional hazards model were used to analyze the date.
Results: The optimum cut-off values of the SUVmax, MTV, TLG, TBR and TLR for predicting tumor progression were 22.25, 256.05, 5 232.67, 12.97 and 10.60, respectively. The patients were divided into two groups according to the above cut-off values, respectively. Kaplan-Meier survival analysis showed that there were statistically significant differences in PFS between the two group (all <0.05). The MTV and TLG values were correlated with NCCN-IPI score, Ann Arbor stage, serum lactate dehydrogenase level, and gene rearrangement (all <0.05). Univariate analysis showed that NCCN-IPI score >3, gene rearrangement positive, SUVmax≥22.25, MTV≥256.05 cm, TLG≥5 232.67 g and TBR≥12.97 were adverse factors for prognosis (: 1.949-5.759, all <0.05). Multivariate Cox regression analysis showed that gene rearrangement positive and TLG≥5 232.67 g were all independent risk factors affecting PFS (: 4.660, 3.350, 4.031, all <0.05).
Conclusion: The F-FDG PET/CT metabolic parameters SUVmax, MTV, TLG, TBR and TLR can be used as important indicators to predict PFS of DLBCL patients, and combining clinicopathological features can better predict the prognosis of patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.19746/j.cnki.issn.1009-2137.2025.02.009 | DOI Listing |
Clin Nucl Med
August 2025
Departments of Radiation Oncology.
Background: To explore the potential utility of 18 F-AlF-NOTA-fibroblast activation protein inhibitor (FAPI)-04 PET/CT (denoted as 18 F-FAPI-04 PET/CT) in the evaluation of cervical cancer through a head-to-head comparison with 18 F-FDG PET/CT for detecting primary tumors and metastatic lymph nodes.
Patients And Methods: A total of 22 patients with a pathologic diagnosis of cervical cancer underwent 18 F-FDG PET/CT and 18 F-FAPI-04 PET/CT within a 7-day period. Out of the 22 patients, 19 (median age, 62.
Quant Imaging Med Surg
September 2025
Department of Nuclear Medicine, The Third Affiliated Hospital of Soochow University, Changzhou, China.
Background: Lymphovascular invasion (LVI) is a critical factor in the lymphatic spread of tumor cells, and is closely associated with local recurrence and distant metastasis in gastric cancer. The study aimed to evaluate the correlation and predictive value of preoperative total lesion glycolysis (TLG) in patients with primary gastric cancer as measured by a combination of F-labeled fluoro-2-deoxyglucose (F-FDG) positron emission tomography (PET) and computed tomography (CT) for LVI.
Methods: A retrospective analysis of the demographic and F-FDG PET/CT data of 177 patients with gastric cancer diagnosed by postoperative pathology at The Third Affiliated Hospital of Soochow University between January 2014 and August 2021 was conducted.
Medicina (Kaunas)
August 2025
Division of Medical Oncology, Department of Internal Medicine, Marmara University School of Medicine, Istanbul 34854, Turkey.
Total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC) offers significant advantages in terms of pathologic response and long-term survival; however, it is still unclear which patients will benefit the most from this treatment. This study aims to investigate the role of metabolic parameters on pretreatment positron emission tomography-computed tomography (PET/CT) images in predicting treatment response after TNT. The research was conducted using a single-center, retrospective design.
View Article and Find Full Text PDFSci Rep
August 2025
Faculty of Medicine, Department of Medical Oncology, Ankara University, Cebeci, Ankara, 06100, Türkiye, Turkey.
Identifying reliable prognostic markers in patients with advanced non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs) is critical for clinical decision-making. This study introduces the Metabolic and Immune Score (MIS), a novel scoring system combining metabolic and inflammatory markers. A retrospective analysis was conducted on 56 patients with advanced NSCLC treated with ICIs between January 2018 and January 2024.
View Article and Find Full Text PDFAcad Radiol
August 2025
Queen Mary College, Nanchang University, No. 1299 Xuefu Avenue, Nanchang City, Jiangxi Province, 330000, China.
Rationale And Objectives: This systematic review and meta-analysis endeavors to elucidate the prognostic value of 18F-FDG PET/CT-derived biomarkers, including maximum standardized uptake value (SUV), metabolic tumor volume (MTV), as well as total lesion glycolysis (TLG), in the follicular lymphoma (FL) population across different disease stages.
Materials And Methods: PubMed, EMBASE, the Cochrane Library, and Web of Science were thoroughly searched from establishment to April 7, 2025. Encompassed studies were methodologically prospective (5) or retrospective (11) cohort investigations into the links of PET/CT parameters to clinical outcomes in FL.